<SEC-DOCUMENT>0001140361-21-000575.txt : 20210108
<SEC-HEADER>0001140361-21-000575.hdr.sgml : 20210108
<ACCEPTANCE-DATETIME>20210108074532
ACCESSION NUMBER:		0001140361-21-000575
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20210108
FILED AS OF DATE:		20210108
DATE AS OF CHANGE:		20210108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nanobiotix S.A.
		CENTRAL INDEX KEY:			0001760854
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39777
		FILM NUMBER:		21515661

	BUSINESS ADDRESS:	
		STREET 1:		60 RUE DE WATTIGNIES
		CITY:			PARIS
		STATE:			I0
		ZIP:			75012
		BUSINESS PHONE:		33140260470

	MAIL ADDRESS:	
		STREET 1:		60 RUE DE WATTIGNIES
		CITY:			PARIS
		STATE:			I0
		ZIP:			75012
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>brhc10018772_6k.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit Financial
         Document created using EDGARfilings PROfile 7.4.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: center; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
      <div>&#160;</div>
      <div style="text-align: center; font-size: 18pt; font-weight: bold;">FORM 6-K</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">Report of Foreign Private Issuer</div>
      <div style="text-align: center; font-weight: bold;">Pursuant to Rule 13a-16 or 15d-16</div>
      <div style="text-align: center; font-weight: bold;">of the Securities Exchange Act of 1934</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">Date of Report: January 8, 2021</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">Commission File Number: 001-39777</div>
      <div>&#160;</div>
      <div style="text-align: center; font-size: 24pt; font-weight: bold;">Nanobiotix S.A.</div>
      <div style="text-align: center; font-weight: bold;">(Exact Name of Registrant as Specified in its Charter)</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">60 Rue de Wattignies</div>
      <div style="text-align: center; font-weight: bold;">75012 Paris, France</div>
      <div style="text-align: center; font-weight: bold;">(Address of principal executive office)</div>
      <div>&#160;</div>
      <div>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</div>
      <div>&#160;</div>
      <div style="text-align: center;">Form 20-F &#9746; Form 40-F &#9744;</div>
      <div>&#160;</div>
      <div>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</div>
      <div>&#160;</div>
      <div>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</div>
      <div> <br>
      </div>
      <div>
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="font-weight: bold;"><u>EXHIBIT INDEX</u></div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="zbfda8fb05e104b42a6eee207b7b4a1a9" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td nowrap="nowrap" style="width: 6%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Exhibit</div>
            </td>
            <td style="width: 2%; vertical-align: bottom;">&#160;</td>
            <td nowrap="nowrap" style="width: 92%; vertical-align: bottom;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Title</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: middle; text-align: center;">&#160;</td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 92%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td nowrap="nowrap" style="width: 6%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0);"><a href="brhc10018772_ex99-1.htm">99.1</a></div>
            </td>
            <td style="width: 2%; vertical-align: bottom;">&#160;</td>
            <td style="width: 92%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Press Release, dated January 8, 2021</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">SIGNATURES</div>
      <div>&#160;</div>
      <div>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z4661fc41bf65411682efac7b0ba547d0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;" rowspan="1" colspan="2">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">NANOBIOTIX S.A.</div>
              <div style="color: rgb(0, 0, 0); font-weight: normal;">(Registrant) </div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 47%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">
              <div style="color: rgb(0, 0, 0);">January 8, 2021</div>
            </td>
            <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
              <div style="color: rgb(0, 0, 0);">By:</div>
            </td>
            <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: rgb(0, 0, 0);">/s/ Philippe Mauberna</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 47%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Philippe Mauberna</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 47%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Chief Financial Officer</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>brhc10018772_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit Financial
         Document created using EDGARfilings PROfile 7.4.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; font-style: italic; font-weight: bold;"> <font style="font-style: normal;">Exhibit 99.1</font><br>
      </div>
      <div style="text-align: right; font-style: italic; font-weight: bold;"><font style="font-style: normal;"> <br>
        </font></div>
      <div style="text-align: center; font-style: italic; font-weight: bold;">
        <div style="text-align: left;">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z33ced0143dce4a718c0271c5aa83977e">

              <tr>
                <td style="background-color: #E0E565; width: 100%;">
                  <div style="margin: 3pt 0px 0px;">&#160;</div>
                </td>
              </tr>

          </table>
        </div>
        <div style="text-align: right;"><img width="234" border="0" height="54" src="image01.jpg" style="margin: 8pt 0px 0px;"></div>
        <div><br>
        </div>
      </div>
      <div style="text-align: center; font-style: italic; font-weight: bold;">PRESS RELEASE</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">NANOBIOTIX ANNOUNCES KEY DEVELOPMENT MILESTONES FOR 2021 AFTER SUCCESSFUL NASDAQ INITIAL PUBLIC OFFERING</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z42ed421375734952a22f710588fbe8c8" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;">Nanobiotix will use a portion of the proceeds from the its IPO to launch its global phase III registration study in head and neck cancer in the United States in 2021</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zd83f65e104a242709d14303c817e7b90" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;">Following previously reported preliminary data regarding the ability of NBTXR3 to help transform anti-PD-1 non-responders into responders, the Company will provide the next update on its immuno-oncology phase I
                basket study evaluating NBTXR3 in combination with anti-PD-1 checkpoint inhibitors in the second quarter of 2021</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z6240c3d0e6024b1ca5d4d45bd972cf8f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;">The Company&#8217;s expansive global development plan for NBTXR3, both as a single agent activated by radiotherapy and in combination with other anti-cancer therapies, will continue as planned</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: justify;"><font style="font-style: italic;">&#8220;Following the successful closing of our initial public offering on Nasdaq in December 2020, Nanobiotix is well positioned to continue global development of NBTXR3 as planned.
          Despite the challenges presented in 2020, our team achieved significant milestones to advance development of our tumor-agnostic lead product candidate across several indications&#8212;both as a single agent activated by radiotherapy and in combination
          with other anti-cancer therapies. In 2021, we intend to continue advancing our priority head and neck cancer pathway, and to generate further evidence that NBTXR3 could improve immunotherapy patient outcomes by increasing the proportion of
          patients that respond to immune checkpoint inhibitors. We will also continue to lay the foundation, to expand our development plan and achieve our mission of offering the potential benefits of NBTXR3 to millions of patients around the world.&#8221; </font>&#8211;
        Laurent Levy, CEO of Nanobiotix</div>
      <div><br>
      </div>
      <div style="text-align: justify;"><font style="font-weight: bold;">Paris, France; Cambridge, Massachusetts (USA); January 8, 2021 &#8211;</font>&#160;<u>NANOBIOTIX</u><u>&#160;</u>(Euronext: NANO &#8211; NASDAQ: NBTX &#8211; the &#8216;&#8216;<font style="font-weight: bold;">Company</font>&#8217;&#8217;),
        a clinical-stage biotechnology company focused on developing first-in-class product candidates that use proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy and increasing the proportion of patients
        that respond to immune checkpoint inhibitors, today announced its global development plan for 2021 and beyond.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Radiotherapy, also called radiation therapy, involves the use of X-rays or other high-energy particles or rays to kill cancer cells in tumors. It is among the most common cancer treatments, both as a standalone
        therapy and in combination with surgery, chemotherapy or biological therapies. In developed countries with access to radiotherapy, approximately 60% of all cancer patients will receive radiotherapy at least once, either alone or as a part of a more
        complex treatment protocol. Nevertheless, many of these patients still die from the progression of their cancer because, among other reasons, they are not able to receive a high enough radiation dose to completely destroy their tumor without
        resulting in an unacceptable level of damage to surrounding healthy tissues.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">The pioneering approach from Nanobiotix uses nanophysics to bring a physical mode of action to destroy cancer cells. Unlike traditional chemotherapies or biologics, NBTXR3 has a broadly applicable mechanism of action
        that has the potential to be used in the treatment of all solid tumor types in conjunction with radiotherapy and other anti-cancer products.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">The Company believes that NBTXR3&#8217;s mode of action could improve outcomes for patient populations across all solid tumors that may be treated with radiotherapy. These patient populations represent a significant market
        opportunity for NBTXR3. Moreover, the Company believes that NBTXR3 could bring new opportunities to patients with cancers that cannot currently be treated with radiotherapy because of the radiosensitivity, or other characteristics, of the tissues
        near the tumor.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Following the successful closing of an initial public offering (IPO) on the Nasdaq stock exchange in the fourth quarter of 2020, the Company&#8217;s strategic long-term goals aim to: (i) complete the development of, and
        satisfy applicable European Union (EU) and United States (US) regulatory requirements for, NBTXR3 for the treatment of locally advanced head and neck cancers; (ii) establish NBTXR3 as a complementary product to immune checkpoint inhibitors; (iii)
        complete the post-approval study for NBTXR3 for the treatment of locally advanced soft tissue sarcoma (STS) in the EU; (iv) expand the opportunity for NBTXR3 as a treatment for solid tumor indications;&#160; and (v) build an effective clinical
        development program and establish a global commercial infrastructure for NBTXR3.</div>
      <div style="text-align: justify;"> <br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
      </div>
      <div style="text-align: center;">
        <div style="text-align: left;">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

              <tr>
                <td style="background-color: #E0E565; width: 100%;">
                  <div style="margin: 3pt 0px 0px;">&#160;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div style="text-align: justify;">
        <div style="text-align: right;"><img width="234" border="0" height="54" src="image01.jpg" style="margin: 8pt 0px 0px;"></div>
      </div>
      <div style="text-align: justify;"> <br>
      </div>
      <div style="text-align: justify;">Development of NBTXR3 as a tumor-agnostic product, both as a single agent activated by radiotherapy and in combination with other anti-cancer therapies, is expected to proceed as follows:</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="2" border="0" id="z7506fbab3a47448bbe4580ce41e1d239" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 36.93%; vertical-align: top; background-color: rgb(118, 113, 113);">
              <div style="text-align: center; color: rgb(255, 255, 255); font-weight: bold;">STUDY</div>
            </td>
            <td style="width: 28.79%; vertical-align: top; background-color: rgb(118, 113, 113);">
              <div style="text-align: center; color: rgb(255, 255, 255); font-weight: bold;">STATUS</div>
            </td>
            <td style="width: 34.28%; vertical-align: top; background-color: rgb(118, 113, 113);">
              <div style="text-align: center; color: rgb(255, 255, 255); font-weight: bold;">ANTICIPATED NEXT STEPS</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top; background-color: rgb(217, 217, 217);" colspan="3">
              <div style="font-weight: bold;">NBTXR3 Activated by Radiotherapy Alone</div>
            </td>
          </tr>
          <tr>
            <td style="width: 36.93%; vertical-align: top; background-color: rgb(175, 171, 171);">
              <div style="font-style: italic; font-weight: bold;">Phase III Registration Study of NBTXR3 in Head and Neck Cancer</div>
              <div>&#160;</div>
              <div>Nanobiotix Study NANORAY-312</div>
            </td>
            <td style="width: 28.79%; vertical-align: top; background-color: rgb(175, 171, 171);">
              <div>Fast Track designation received for patient population from US Food and Drug Administration (FDA)</div>
              <div>&#160;</div>
              <div>Funding for initiation secured through IPO</div>
              <div>&#160;</div>
            </td>
            <td style="width: 34.28%; vertical-align: top; background-color: rgb(175, 171, 171);">
              <div>2021 &#8211; Expect first patients injected (FPI)</div>
              <div>&#160;</div>
              <div>Futility analysis expected 18 months after FPI; interim analysis expected 24-30 months after FPI</div>
            </td>
          </tr>
          <tr>
            <td style="width: 36.93%; vertical-align: top; background-color: rgb(175, 171, 171);">
              <div style="font-style: italic; font-weight: bold;">Phase I Expansion Study of NBTXR3 in Head and Neck Cancer</div>
              <div>&#160;</div>
              <div>Nanobiotix Study 102 Expansion</div>
            </td>
            <td style="width: 28.79%; vertical-align: top; background-color: rgb(175, 171, 171);">
              <div>Dose Expansion &#8211; 51 patients injected as of December 31, 2020</div>
              <div>&#160;</div>
              <div>35 of 44 patients deemed evaluable to date</div>
              <div>&#160;</div>
            </td>
            <td style="width: 34.28%; vertical-align: top; background-color: rgb(175, 171, 171);">
              <div>2Q 2021 &#8211; Expect next results with new evaluable patients and additional follow up on patients treated</div>
              <div>&#160;</div>
              <div>Follow up and evaluation ongoing</div>
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 36.93%; vertical-align: top; background-color: rgb(175, 171, 171);">
              <div style="font-style: italic; font-weight: bold;">Phase I Study of NBTXR3 in Liver Cancer</div>
              <div>&#160;</div>
              <div>Nanobiotix Study 103</div>
            </td>
            <td style="width: 28.79%; vertical-align: top; background-color: rgb(175, 171, 171);">
              <div>Complete</div>
              <div>&#160;</div>
              <div>Recommended phase II dose (RP2D) established at 42% of tumor volume</div>
            </td>
            <td style="width: 34.28%; vertical-align: top; background-color: rgb(175, 171, 171);">
              <div>1Q 2021 &#8211; Final presentation of phase I results</div>
              <div> &#160;</div>
              <div>Next steps to be defined post Study 312 launch</div>
            </td>
          </tr>
          <tr>
            <td style="width: 36.93%; vertical-align: top; background-color: rgb(175, 171, 171);">
              <div style="font-style: italic; font-weight: bold;">Post-Registrational Study of NBTXR3 in Soft Tissue Sarcoma</div>
              <div>&#160;</div>
              <div>Nanobiotix Study 401</div>
            </td>
            <td style="width: 28.79%; vertical-align: top; background-color: rgb(175, 171, 171);">
              <div>In preparation</div>
            </td>
            <td style="width: 34.28%; vertical-align: top; background-color: rgb(175, 171, 171);">
              <div>2H 2021 &#8211; Expected study launch in EU</div>
            </td>
          </tr>
          <tr>
            <td style="width: 36.93%; vertical-align: top; background-color: rgb(219, 229, 241);">
              <div style="font-style: italic; font-weight: bold;">Phase I Study of NBTXR3 in Pancreatic Cancer</div>
              <div>&#160;</div>
              <div>The University of Texas MD Anderson Cancer Center (MD Anderson) Study<font style="font-weight: bold; font-style: italic;">&#160;</font>2019-1001</div>
            </td>
            <td style="width: 28.79%; vertical-align: top; background-color: rgb(219, 229, 241);">
              <div>Active</div>
              <div>&#160;</div>
              <div>First patient injected</div>
            </td>
            <td style="width: 34.28%; vertical-align: top; background-color: rgb(219, 229, 241);">
              <div>2021 &#8211; Recruitment ongoing</div>
              <div>&#160;</div>
              <div>Updates to be provided as they are made available by MD Anderson</div>
            </td>
          </tr>
          <tr>
            <td style="width: 36.93%; vertical-align: top; background-color: rgb(219, 229, 241);">
              <div style="font-style: italic; font-weight: bold;">Phase I Study of NBTXR3 in Lung Cancer Amenable to Re-irradiation</div>
              <div>&#160;</div>
              <div>MD Anderson Study<font style="font-weight: bold; font-style: italic;">&#160;</font>2020-0123</div>
            </td>
            <td style="width: 28.79%; vertical-align: top; background-color: rgb(219, 229, 241);">
              <div>Received FDA &#8216;Safe to Proceed&#8217;</div>
              <div>&#160;</div>
              <div>Pending activation</div>
            </td>
            <td style="width: 34.28%; vertical-align: top; background-color: rgb(219, 229, 241);">
              <div>1H 2021 &#8211; Expected study launch</div>
              <div>&#160;</div>
              <div>Updates to be provided as they are made available by MD Anderson</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top; background-color: rgb(217, 217, 217);" colspan="3">
              <div style="font-weight: bold;">NBTXR3 Activated by Radiotherapy in Combination with Immune Checkpoint Inhibitors</div>
            </td>
          </tr>
          <tr>
            <td style="width: 36.93%; vertical-align: top; background-color: rgb(166, 166, 166);">
              <div style="font-style: italic; font-weight: bold;">Phase I Basket Study of NBTXR3 in Combination with Anti-PD-1 for Patients with Head and Neck Cancer, Lung Metastasis and/or Liver Metastasis</div>
              <div>&#160;</div>
              <div>Nanobiotix Study 1100</div>
            </td>
            <td style="width: 28.79%; vertical-align: top; background-color: rgb(166, 166, 166);">
              <div>Positive first results presented at SITC 2020</div>
              <div>&#160;</div>
              <div>Recruitment ongoing</div>
            </td>
            <td style="width: 34.28%; vertical-align: top; background-color: rgb(166, 166, 166);">
              <div>2Q 2021 &#8211;Updated results with new patients and additional follow up expected</div>
              <div>&#160;</div>
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 36.93%; vertical-align: top; background-color: rgb(219, 229, 241);">
              <div style="font-style: italic; font-weight: bold;">Phase II Study of NBTXR3 in Combination with Anti-PD-1 for Patients with Recurrent/Metastatic Head and Neck Cancer with Limited PD-L1 Expression</div>
              <div>&#160;</div>
              <div>MD Anderson Study 2020-0541</div>
            </td>
            <td style="width: 28.79%; vertical-align: top; background-color: rgb(219, 229, 241);">
              <div>Received FDA &#8216;Safe to Proceed&#8217;</div>
              <div>&#160;</div>
              <div>Pending activation</div>
            </td>
            <td style="width: 34.28%; vertical-align: top; background-color: rgb(219, 229, 241);">
              <div>1H 2021 &#8211; Expected launch and first patient injected</div>
              <div>&#160;</div>
              <div>Updates to be provided as they are made available by MD Anderson</div>
            </td>
          </tr>
          <tr>
            <td style="width: 36.93%; vertical-align: top; background-color: rgb(219, 229, 241);">
              <div style="font-style: italic; font-weight: bold;">Phase II Study of NBTXR3 in Combination with Anti-PD-1/L1 for Patients with Inoperable Head and Neck Cancer Amenable to Re-irradiation</div>
              <div>&#160;</div>
              <div>MD Anderson Study 2020-0354</div>
            </td>
            <td style="width: 28.79%; vertical-align: top; background-color: rgb(219, 229, 241);">
              <div>Received FDA &#8216;Safe to Proceed&#8217;</div>
              <div>&#160;</div>
              <div>Pending activation</div>
            </td>
            <td style="width: 34.28%; vertical-align: top; background-color: rgb(219, 229, 241);">
              <div>1H 2021 &#8211; Expected launch and first patients injected</div>
              <div>&#160;</div>
              <div>Updates to be provided as they are made available by MD Anderson</div>
            </td>
          </tr>
          <tr>
            <td style="width: 36.93%; vertical-align: top; background-color: rgb(219, 229, 241);">
              <div><font style="font-weight: bold; font-style: italic;">Phase I Study of NBTXR3 in combination with Anti-CTLA-4 and Anti-PD-1/L1 plus RadScopal</font>&#8482;<font style="font-weight: bold; font-style: italic;"> in Advanced Solid Tumors with Lung
                  or Liver Metastasis</font></div>
              <div>&#160;</div>
              <div>MD Anderson Study (2020-0618)</div>
            </td>
            <td style="width: 28.79%; vertical-align: top; background-color: rgb(219, 229, 241);">
              <div>In preparation</div>
            </td>
            <td style="width: 34.28%; vertical-align: top; background-color: rgb(219, 229, 241);">
              <div>2021 &#8211; Expected launch and first patient injected</div>
              <div>&#160;</div>
              <div>Updates to be provided as they are made available by MD Anderson</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top; background-color: rgb(217, 217, 217);" colspan="3">
              <div style="font-weight: bold;">NBTXR3 Activated by Radiotherapy in Combination with Concurrent Chemotherapy</div>
            </td>
          </tr>
          <tr>
            <td style="width: 36.93%; vertical-align: top; background-color: rgb(219, 229, 241);">
              <div style="font-weight: bold;"><font style="font-style: italic;">Phase I Study of NBTXR3 in</font>&#160;<font style="font-style: italic;">Esophageal Cancer</font></div>
              <div>&#160;</div>
              <div>MD Anderson Study<font style="font-weight: bold; font-style: italic;">&#160;</font>2020-0122</div>
            </td>
            <td style="width: 28.79%; vertical-align: top; background-color: rgb(219, 229, 241);">
              <div>Active</div>
              <div>&#160;</div>
              <div>Not yet recruiting</div>
            </td>
            <td style="width: 34.28%; vertical-align: top; background-color: rgb(219, 229, 241);">
              <div>1H 2021 &#8211; Expect first patient injected</div>
              <div>&#160;</div>
              <div>Updates to be provided as they are made available by MD Anderson</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
      </div>
      <div style="text-align: center;">
        <div style="text-align: left;">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

              <tr>
                <td style="background-color: #E0E565; width: 100%;">
                  <div style="margin: 3pt 0px 0px;">&#160;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div style="text-align: center;">
        <div style="text-align: right;"><img width="234" border="0" height="54" src="image01.jpg" style="margin: 8pt 0px 0px;"></div>
      </div>
      <div style="text-align: center;"> <br>
      </div>
      <div style="text-align: justify;">Below is an overview of the Company&#8217;s most advanced clinical studies.</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-weight: bold;">Development of NBTXR3 as a Single Agent Activated by Radiotherapy Alone</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-style: italic;">Locally Advanced Head and Neck Cancers</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Background and Opportunity:</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Head and neck cancers include cancers of the oral cavity, tongue and oropharynx, a part of the throat. These structures play a critical role in a human&#8217;s ability to swallow, breathe and speak. The American Cancer
        Society estimates that in 2020 in the United States, approximately 53,260 patients will be diagnosed with oral or oropharyngeal cancer and approximately 10,750 patients will die from the cancer. According to 2018 estimates by the Global Cancer
        Observatory, part of the World Health Organization&#8217;s International Agency for Research on Cancer, around 890,000 patients are diagnosed globally each year with head and neck cancer. The five-year survival rate for patients with oral and
        oropharyngeal cancer is approximately 65%. These cancers represent a major public health concern.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Chemotherapy in combination with concomitant radiation is the standard treatment for locally advanced head and neck cancers in both the United States and the EU. However, it is often not an option for elderly
        patients who are unable to endure the physical strain inherent in chemotherapy treatment. The alternative treatment to chemoradiation is cetuximab in combination with radiotherapy, but it has a limited efficacy in elderly patients. These patients
        are estimated to account for approximately 25% of patients with head and neck cancers. In data presented at the Multidisciplinary Head and Neck Cancers Symposium 2020, elderly patients treated with radiotherapy alone or radiotherapy in combination
        with cetuximab had a median PFS of 7.3 months. Elderly patients with locally advanced tumors who receive radiation also generally have short OS rates (median of 12 months following diagnosis, based on our review and sub-group analysis of scientific
        literature relating to head and neck cancers) and typically experience poor quality of life, as they have limited therapeutic options and a high unmet medical need.</div>
      <div><br>
      </div>
      <div style="text-align: justify;"><u>Phase III Registration Study in Head and Neck Cancer (Nanobiotix Study NANORAY-312)</u></div>
      <div><br>
      </div>
      <div style="text-align: justify;">In February 2020,&#160; Nanobiotix submitted the NANORAY-312 protocol to the FDA for review, a global Phase III clinical study for elderly patients with locally-advanced head and neck cancer who are ineligible for
        platinum-based (cisplatin) chemotherapy. The Company is in the process of making final protocol refinements in response to FDA feedback and intend to initiate Study NANORAY-312 with a portion of the proceeds from the Company&#8217;s Nasdaq IPO.&#160;
        Nanobiotix expects the study to launch in the United States in 2021.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Also in February 2020, the Company received Fast Track designation from the FDA for NBTXR3 in this patient population. Fast Track designation is a process designed to facilitate the development and accelerate the
        review of treatments for serious conditions and that have the potential to address unmet medical needs. We may also potentially pursue Breakthrough Therapy designation.</div>
      <div><br>
      </div>
      <div style="text-align: justify;"><u>Phase I Dose Expansion Study in Head and Neck Cancer (Nanobiotix Study 102 Expansion)</u></div>
      <div><br>
      </div>
      <div style="text-align: justify;">The Company is in the process of conducting the dose expansion part of a phase I clinical trial of NBTXR3 activated by intensity-modulated radiation therapy (IMRT) in patients with locally advanced squamous cell
        carcinoma of the oral cavity or oropharynx who are ineligible for cisplatin or intolerant to cetuximab. The expansion cohort utilizes the highest dose level (22%) from the dose escalation portion of Study 102 in order to potentially strengthen
        preliminary efficacy data from that initial phase. As of December 2020, 51 have been injected in Study 102 Expansion. To date, 35 of the necessary 44 patients have been deemed evaluable. Follow up and evaluation remain ongoing.&#160; Nanobiotix
        presented preliminary efficacy and safety results from Study 102 Expansion in October 2020 at the annual meeting of the American Society for Radiation Oncology (ASTRO).</div>
      <div style="text-align: justify;"> <br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
      </div>
      <div style="text-align: center;">
        <div style="text-align: left;">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

              <tr>
                <td style="background-color: #E0E565; width: 100%;">
                  <div style="margin: 3pt 0px 0px;">&#160;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div style="text-align: center;">
        <div style="text-align: right;"><img width="234" border="0" height="54" src="image01.jpg" style="margin: 8pt 0px 0px;"></div>
      </div>
      <div style="text-align: justify;"> <br>
      </div>
      <div style="text-align: justify;">Next results will be presented during the International Organization for Medical Physics (IOMP) week in the second quarter of 2021.</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-style: italic;">Hepatocellular Carcinoma and Liver Metastasis</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Background and Opportunity:</div>
      <div><br>
      </div>
      <div style="text-align: justify;">According to the World Health Organization, liver cancer is currently the fourth most common cause of cancer death in the world and is estimated to have caused over 781,000 deaths in 2018. The American Cancer Society
        estimated that in 2020 in the United States, 42,810 people would be diagnosed with liver cancer and 30,160 patients would die of the disease. In Europe, an estimated 47,000 patients die of liver cancer each year. The five-year survival rate for
        patients with localized liver cancer is approximately 31%; once the cancer has spread to other organs or tissues, this survival rate drops to approximately 3%.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Two types of liver cancer are hepatocellular carcinoma (HCC), the most common type of liver cancer, and secondary liver cancer, or liver metastasis, which occurs when cancer from another part of the body spreads to
        the liver. Surgical resection is often not an option for patients with either HCC or liver metastasis. Moreover, because patients suffering from HCC or liver metastases typically have underlying liver dysfunction and concomitant malignancies, local
        and systemic treatment options are few in number, with significant limitations. Stereotactic body radiation therapy (SBRT)&#8212;a high-precision radiation therapy, delivered as high-energy dose fractions&#8212;is a prevalent alternative therapy that has been
        shown to improve outcomes for these patients, as third-party clinical studies have observed a direct correlation between higher doses of radiation and increased survival rates. However, SBRT dosage is limited due to potential toxicity to
        surrounding tissues and the need to preserve liver function. The Company&#8217;s ongoing phase I/II clinical study described below evaluated NBTXR3 in patients with liver cancers in need of an alternative treatment, when standard care protocols either
        cannot be used or do not exist. By increasing the absorption of the administered SBRT dose within the tumor itself, without causing additional damage to surrounding healthy tissues, and causing more effective tumor destruction, Nanobiotix believes
        NBTXR3 can improve prognoses for this patient population.</div>
      <div><br>
      </div>
      <div style="text-align: justify;"><u>Phase I Study of NBTXR3 for Patients with HCC and Liver Metastasis (Nanobiotix Study 103)</u></div>
      <div><br>
      </div>
      <div style="text-align: justify;">Nanobiotix has completed its phase I study evaluating the use of NBTXR3 activated by SBRT in liver cancers. The study was conducted at six sites in the EU. The Company recruited 23 patients, divided in two subgroups:
        patients with primary liver cancer (HCC) and patients with secondary liver cancer (liver metastases).</div>
      <div><br>
      </div>
      <div style="text-align: justify;">The endpoint of the study was determination of the RP2D of NBTXR3 and to assess early signs of anti-tumor activity. Patients received a single intra-lesional injection of NBTXR3, at increasing dose levels, in each
        case activated by SBRT.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">The final presentation of results from Study 103 will be delivered at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) in the first quarter of 2021.</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-style: italic;">Locally Advanced Soft Tissue Sarcoma</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Background and Opportunity:</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Soft tissue sarcomas (STSs) are rare cancers that develop in different types of soft tissues, including muscles, joint structures, fat, nerves and blood vessels. Although STS can develop at any anatomic site, it
        occurs in the extremities (arms and legs) in approximately 60% of cases. The American Cancer Society estimates that in 2020 in the United States, approximately 13,130 patients will be diagnosed with STS, and approximately 5,350 STS patients will
        die from this cancer. In the EU, over 23,000 patients are diagnosed with STS each year. The National Cancer Institute estimates that the five-year survival rate for STS patients is approximately 65%. Median overall survival for patients with
        advanced, metastatic STS is estimated to be 18-19 months. Radiotherapy followed by surgery is part of the typical treatment regimen for STS patients in Europe.</div>
      <div style="text-align: justify;"> <br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
      </div>
      <div style="text-align: center;">
        <div style="text-align: left;">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

              <tr>
                <td style="background-color: #E0E565; width: 100%;">
                  <div style="margin: 3pt 0px 0px;">&#160;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div style="text-align: center;">
        <div style="text-align: right;"><img width="234" border="0" height="54" src="image01.jpg" style="margin: 8pt 0px 0px;"></div>
      </div>
      <div style="text-align: justify;"> <br>
      </div>
      <div style="text-align: justify;">Achieving local control of the tumor is critical to improving survival rates and reducing the need for limb amputations. Patients with locally advanced STS are high-risk patients and have few therapeutic options
        capable of achieving local control. Consequently, innovative treatments to improve cancer cell destruction and the feasibility of surgical resection are needed. NBTXR3, when activated by radiotherapy, is designed to enhance the efficacy of
        radiation both by destroying more tumor cells and rendering the tumor more susceptible to surgical resection, thereby improving patient outcomes.</div>
      <div><br>
      </div>
      <div style="text-align: justify;"><u>Post-Registrational Study of NBTXR3 in Soft Tissue Sarcoma of the Extremities and Trunk Wall (Nanobiotix Study 401)</u></div>
      <div><br>
      </div>
      <div style="text-align: justify;">In April 2019, Nanobiotix completed the regulatory process for the CE mark of NBTXR3 based on positive results from the Company&#8217;s phase II/III study evaluating the product candidate for patients with advanced STS of
        the extremities and trunk, thereby allowing the product to be commercialized in the 27 EU countries under the brand name Hensify<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"> &#174;</sup>. Nanobiotix is currently preparing a post-registrational study (Study 401) that will continue evaluating
        the safety and efficacy of Hensify<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#160;</sup> while providing patients with access to the product. We expect approximately 100 patients to be recruited as part of Study 401, which is expected to launch in Europe in the second half of 2021.
        Following evaluation of the results from Studies 102 and 312, we intend to continue our&#160; strategic review and to consider the optimal approach to the commercialization of Hensify.</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-style: italic;">Pancreatic Cancer</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Background and Opportunity:</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Pancreatic cancer is a rare, deadly disease. Worldwide, there were approximately 460,000 new cases in 2018. Given that surgery with R0 resection (i.e., macroscopically complete tumor removal with negative microscopic
        surgical margins) remains the only hope for long-term survival, clinical studies have investigated various neoadjuvant strategies&#8212;wherein patients receive anti-cancer drugs or radiation prior to surgery&#8212;to increase the surgery-eligible population
        while also increasing the R0 resection rate. According to the American Cancer Society, for all stages of pancreatic cancer combined, the one-year relative survival rate is 20%, and the five-year rate is 7%.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">In support of the rationale for neoadjuvant therapy, a retrospective analysis demonstrated a near doubling in OS in pancreatic ductal adenocarcinoma (&#8220;PDAC&#8221;) patients who underwent surgery, which was attributed, at
        least in part, to the increased proportion of borderline resectable pancreatic cancer (&#8220;BRPC&#8221;) patients who became eligible for surgery as a result of neoadjuvant intervention. Importantly, there are also select cases of locally advanced pancreatic
        cancer (&#8220;LAPC&#8221;) patients being considered for surgical resection based on their response to therapy. Given the poor prognosis of PDAC, therapeutic regimens able to increase the proportion of BRPC and LAPC patients eligible for surgery could improve
        survival outcomes in this population with unmet need.</div>
      <div><br>
      </div>
      <div style="text-align: justify;"><u>Phase I Study of NBTXR3 for Patients with Pancreatic Cancer (MD Anderson Study 2019-1001)</u></div>
      <div><br>
      </div>
      <div style="text-align: justify;">This MD Anderson study is an open-label, single-arm, prospective phase I study consisting of two parts: (i) dose-escalation to determine the RP2D; and (ii) expansion at RP2D.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">In May 2020, we announced that the FDA allowed the clinical study protocol to proceed, and we dosed the first patient in this study during September 2020. Recruitment is expected to remain ongoing throughout 2021 and
        additional updates will be provided as they are made available by MD Anderson.</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-style: italic;">Lung Cancer</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Background and Opportunity:</div>
      <div><br>
      </div>
      <div style="text-align: justify;">According to the World Health Organization, lung cancer is currently the most common cause of cancer death in the world and is estimated to have caused over 1,761,000 deaths in 2018. According to the American Cancer
        Society, in 2020 it is estimated that there will be approximately 228,000 new cases of lung cancer diagnosed in the United States. It is estimated that in the United States there will be approximately 135,720 deaths from lung cancer in 2020.
        Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 84% of all lung cancer diagnoses. The five-year relative survival rate for NSCLC at all stages was 24%.</div>
      <div style="text-align: justify;"> <br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
      </div>
      <div style="text-align: center;">
        <div style="text-align: left;">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

              <tr>
                <td style="background-color: #E0E565; width: 100%;">
                  <div style="margin: 3pt 0px 0px;">&#160;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div style="text-align: center;">
        <div style="text-align: right;"><img width="234" border="0" height="54" src="image01.jpg" style="margin: 8pt 0px 0px;"></div>
      </div>
      <u> <br>
      </u>
      <div style="text-align: justify;"><u>Phase I Study of NBTXR3 for patients with Lung Cancer Amenable to Re-irradiation (MD Anderson Study 2020-0123)</u></div>
      <div><br>
      </div>
      <div style="text-align: justify;">This MD Anderson study is an open-label, two-cohort, prospective phase I study consisting of two parts: (i) a radiation therapy safety lead-in, and NBTXR3 activated by radiation therapy dose-finding to determine the
        RP2D, and (ii) expansion at RP2D with toxicity monitoring.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">The patient population will include adults (age &#8805; 18) with inoperable, locoregional recurrent (&#8220;LRR&#8221;) non-small cell lung cancer (NSCLC) stage IA to IIIC that are radiographically non-metastatic at screening and have
        previously received definitive radiation therapy. The number of participants enrolled will be determined based on the maximum number required to establish the RP2D. Cohort 1 will evaluate the safety of intensity-modulated radiation therapy (&#8220;IMRT&#8221;)
        monotherapy in 10 patients using an approach similar to a 3+3 design. If 45 Gy in 15 fractions is deemed safe, cohort 2 will test that regimen with NBTXR3 activated by IMRT. Alternatively, if 45 Gy in 15 fractions is deemed to have excessive
        toxicity, a 30 Gy in 10 fractions regimen will be used in combination with NBTXR3 in cohort 2. Up to 24 subjects will be enrolled in cohort 2, including a maximum of 12 subjects for the dose-finding part. Twelve additional subjects will be enrolled
        for the NBTXR3 RP2D expansion. Study initiation is expected in the first half of 2021, and the planned enrollment period is 36 months.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">The launch of this study has been delayed by logistical constraints associated with the COVID-19 pandemic. Updates will be provided as they are made available by MD Anderson.</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-weight: bold;">Development NBTXR3 Activated by Radiotherapy in Combination with Immune Checkpoint Inhibitors (Immuno-Oncology Program)</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Background and Opportunity:</div>
      <div><br>
      </div>
      <div style="text-align: justify;">In recent years, significant attention has been focused on the potential of immuno-oncology (I-O) treatments, and in particular, checkpoint inhibitors. Checkpoint inhibitors are a type of immunotherapy that function
        to block proteins that stop the immune system from attacking cancer cells. In doing so, they enable the T cells to recognize cancer cells that would otherwise be invisible to immune attack. However, many tumors, which are referred to as &#8220;cold&#8221;
        tumors, exhibit little or no response to checkpoint inhibition.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Cancer immunotherapy is becoming a major treatment paradigm for a variety of cancers. Although immunotherapy, especially the use of immune checkpoint inhibitors, has achieved clinical success, most cancer patients
        present resistance to I-O treatments. In fact, published scientific data shows that only 15%-20% of non-small cell lung cancer patients and 13%-22% of head and neck squamous cell carcinoma patients respond to immune checkpoint inhibitors. We
        believe that NBTXR3 activated by radiotherapy in combination with immune checkpoint inhibitors has the potential to unlock the potential of I-O treatments by converting checkpoint inhibitor non-responders into responders.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Our preclinical and early clinical study results suggest that NBTXR3-enhanced radiotherapy may prime the immune response, thereby rendering otherwise cold tumors more prone to recognition by the patient&#8217;s immune
        system and therefore more responsive to I-O treatments such as checkpoint inhibitors. This effect is also referred to as causing a &#8220;cold&#8221; tumor to become &#8220;hot.&#8221;</div>
      <div><br>
      </div>
      <div style="text-align: justify;"><u>Phase I Basket Study of NBTXR3 in Combination with Anti-PD-1 for Patients with Head and Neck Cancer, Lung Metastasis and/or Liver Metastasis (Nanobiotix Study 1100)</u></div>
      <div><br>
      </div>
      <div style="text-align: justify;">Nanobiotix presented positive first clinical results from Study 1100 at the SITC 35<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Annual Meeting in November 2020. Recruitment in the study remains ongoing, and the Company expects updated results with
        new patients and additional follow-up at the Annual Meeting of the American Society for Clinical Oncology in the second quarter of 2021.</div>
      <div><br>
      </div>
      <div style="text-align: justify;"><u>Phase II Study of NBTXR3 in Combination with Anti-PD-1 for Patients with Recurrent/Metastatic Head and Neck Cancer with Limited PD-L1 Expression (MD Anderson Study Number 2020-0541)</u></div>
      <div><br>
      </div>
      <div style="text-align: justify;">This MD Anderson study is an open label, two cohort, non-randomized phase II study. The primary objective of the study is to evaluate tumor response of NBTXR3 activated by radiation therapy in combination with
        pembrolizumab in patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) with limited PD-L1 expression.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Nanobiotix expects this study to launch and inject the first patient in 2021. Updates will be provided as they are made available by MD Anderson.</div>
      <div style="text-align: justify;"> <br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
      </div>
      <div style="text-align: center;">
        <div style="text-align: right;">
          <div>
            <div style="text-align: left;">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                  <tr>
                    <td style="background-color: #E0E565; width: 100%;">
                      <div style="margin: 3pt 0px 0px;">&#160;</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
          <img width="234" border="0" height="54" src="image01.jpg" style="margin: 8pt 0px 0px;"></div>
      </div>
      <div style="text-align: justify;"><u> <br>
        </u></div>
      <div style="text-align: justify;"><u>Phase II Study of NBTXR3 in Combination with Anti-PD-1 for Patients with Head and Neck Cancer Amenable to Re-Irradiation (MD Anderson Study Number 2020-0354)</u></div>
      <div><br>
      </div>
      <div style="text-align: justify;">This MD Anderson study is an open label, two cohort, non-randomized phase II study. The primary objectives of the study are: (i) to estimate progression-free survival (PFS) and the early clinical benefit in patients
        treated with NBTXR3 activated by SBRT re-irradiation, with concurrent pembrolizumab; (ii) to assess the safety profile and estimate the early clinical benefit of NBTXR3 activated by a reduced dose of IMRT or IMPT re-irradiation with concurrent
        pembrolizumab.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Nanobiotix expects this study to launch and inject the first patient in 2021. Updates will be provided as they are made available by MD Anderson.</div>
      <div><br>
      </div>
      <div style="text-align: justify;"><u>Phase I Study of NBTXR3 in Combination with Anti-PD-1 and Anti-CTLA-4 plus RadScopal for Patients with Advanced Solid Tumors and Lung or Liver Metastasis (MD Anderson Study Number 2020-0618)</u></div>
      <div><br>
      </div>
      <div style="text-align: justify;">This MD Anderson study is currently in the early stages of the regulatory review process. Nanobiotix expects this study to launch and inject the first patient in 2021. Updates will be provided as they are made
        available by MD Anderson.</div>
      <div><br>
      </div>
      <div style="font-weight: bold;">Development of NBTXR3 Activated by Radiotherapy in Combination with Concurrent Chemotherapy</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-style: italic;">Esophageal Cancer</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Background and Opportunity:</div>
      <div><br>
      </div>
      <div style="text-align: justify;">According to the World Health Organization, esophageal cancer is currently the sixth most common cause of cancer death in the world and is estimated to have caused over 508,585 deaths in 2018. The American Cancer
        Society estimates that in 2020 in the United States, there will be approximately 18,440 new esophageal cancer cases diagnosed, and approximately 16,170 deaths due to esophageal cancer. Approximately 20% of patients survive esophageal cancer at
        least five years after diagnoses.</div>
      <div><br>
      </div>
      <div style="text-align: justify;"><u>Phase I Study of NBTXR3 for Patients with Esophageal Cancer (MD Anderson Study 2020-0122)</u></div>
      <div><br>
      </div>
      <div style="text-align: justify;">The FDA has indicated that our Phase I clinical study of NBTXR3 with MD Anderson for patients with esophageal cancer may proceed.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">This study is an open-label, single-arm, prospective phase I study consisting of two parts: (i) does-escalation to determine the RP2D of NBTXR3 activated by radiotherapy with concurrent chemotherapy, and (ii)
        expansion at RP2D with toxicity monitoring.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">The patient population will include adults (age &#8805; 18 years) with stage II-III adenocarcinoma of the esophagus that are treatment na&#239;ve and radiographically non-metastatic at screening. The number of participants
        enrolled will be determined based on the maximum number required to establish the RP2D of NBTXR3 activated by radiation therapy. Up to 24 subjects will be enrolled, including a maximum of 12 subjects for the dose-finding part. Twelve additional
        subjects will be enrolled for the RP2D expansion. Recruitment and first injections are expected to begin in the first half of 2021 and the planned enrollment period is 24 months.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">The launch of this study has been delayed by logistical constraints associated with the COVID-19 pandemic. Updates will be provided as they are made available by MD Anderson.</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-weight: bold;">PharmaEngine Trials</div>
      <div style="text-align: justify;"> <br>
      </div>
      <div style="text-align: justify;">Pursuant to a License and Collaboration Agreement with PharmaEngine, Inc., three NBTXR3 clinical trials are currently being run in Asia by PharmaEngine.&#160; These trials include a phase III study of NBTXR3 activated by
        radiotherapy for patients with soft tissue sarcoma, a phase I/II study of NBTXR3 activated by radiotherapy with concurrent chemotherapy for patients with rectal cancer, and a phase I/II study of NBTXR3 activated by radiotherapy with concurrent
        chemotherapy for patients with head and neck cancer.</div>
      <div style="text-align: justify;"> <br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
      </div>
      <div style="text-align: center;">
        <div style="text-align: right;">
          <div>
            <div style="text-align: left;">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                  <tr>
                    <td style="background-color: #E0E565; width: 100%;">
                      <div style="margin: 3pt 0px 0px;">&#160;</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
          <img width="234" border="0" height="54" src="image01.jpg" style="margin: 8pt 0px 0px;"></div>
        <div><br>
        </div>
      </div>
      <div style="text-align: justify;">Results from the rectal cancer study will be presented at the 2021 American Society of Clinical Oncology Gastrointestinal Symposium. Further updates will be provided as they are made available by PharmaEngine.</div>
      <div><br>
      </div>
      <div style="text-align: center; margin-right: 14.15pt;">***</div>
      <div style="text-align: justify; font-weight: bold;">About NBTXR3</div>
      <div style="text-align: justify;">NBTXR3 is a <a name="z_cp_text_1_122"></a>novel, potentially first-in-class product <a name="z_cp_text_1_123"></a>candidate designed to destroy tumors through physical cell death when activated by radiotherapy.
        NBTXR3 has a high degree of biocompatibility, requires one single administration before the first radiotherapy treatment session, and has the ability to fit into current worldwide standards of radiation care. The physical mode of action of NBTXR3
        makes it applicable across solid tumors such as lung, prostate, liver, glioblastoma, and breast cancers.</div>
      <div><br>
      </div>
      <div style="text-align: justify;"><font style="font-weight: bold;">About NANOBIOTIX</font><font style="font-weight: bold;">: </font>www.nanobiotix.com</div>
      <div style="text-align: justify;"><a name="z_Hlk508818390"></a>Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart
        of the cell.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Nanobiotix&#8217;s <a name="z_cp_text_1_124"></a>novel, potentially first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotix&#8217;s Immuno-Oncology
        program has the potential to bring a new dimension to cancer immunotherapies.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP)<a name="z_cp_text_1_125"></a><u style="border-bottom: 1px solid;">&#160;</u>and on the Nasdaq
        Global Select Market (Nasdaq: NBTX). The Company&#8217;s headquarters are in Paris, France, with a U.S. affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany</div>
      <div><br>
      </div>
      <div style="text-align: justify; margin-right: 14.4pt; font-weight: bold;">Contacts</div>
      <table cellspacing="0" cellpadding="0" border="0" id="ze557b4bf6cac4475b79bffda43ede373" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="vertical-align: top;" colspan="2">
              <div style="text-align: center; margin-right: 14.4pt; font-style: italic;">Nanobiotix</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="vertical-align: top; width: 50%;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="margin-right: 14.4pt; font-weight: bold;">Communications Department</div>
              <div style="margin-right: 14.4pt; font-style: italic;">Brandon Owens</div>
              <div style="margin-right: 14.4pt; font-style: italic;">VP, Communications</div>
              <div style="margin-right: 14.4pt;">+1 (617) 852-4835</div>
              <div style="margin-right: 14.4pt;"><u>contact@nanobiotix.com</u></div>
            </td>
            <td style="vertical-align: top; width: 50%;">
              <div style="margin-right: 14.4pt; font-weight: bold;">Investor Relations Department</div>
              <div style="margin-right: 14.4pt; font-style: italic;">Ricky Bhajun</div>
              <div style="margin-right: 14.4pt; font-style: italic;">Senior Manager, Investor Relations</div>
              <div style="margin-right: 14.4pt;">+33 (0)1 79 97 29 99</div>
              <div style="margin-right: 14.4pt;"><u>investors@nanobiotix.com</u></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align: top;" colspan="2" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align: top;" colspan="2">
              <div style="text-align: center; margin-right: 14.4pt; font-style: italic;">Media Relations</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 50%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="margin-right: 14.4pt;">France &#8211; <font style="font-weight: bold;">Ulysse Communication</font></div>
              <div style="margin-right: 14.4pt;">Pierre-Louis Germain</div>
              <div style="margin-right: 14.4pt;">+ 33 (0) 6 64 79 97 51</div>
              <div style="margin-right: 14.4pt;"> <u>plgermain@ulysse-communication.com</u></div>
            </td>
            <td style="width: 50%; vertical-align: top;">
              <div style="margin-right: 14.4pt;">US &#8211; <font style="font-weight: bold;">Porter Novelli</font></div>
              <div style="margin-right: 14.4pt;">Stefanie Tuck</div>
              <div style="margin-right: 14.4pt;">+1 (917) 390-1394</div>
              <div style="margin-right: 14.4pt;"><u>Stefanie.tuck@porternovelli.com</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-right: 14.15pt;"><br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z9d47aa77071d40789ffbec2ac1eb0a5b">

            <tr>
              <td style="width: 25%; vertical-align: top;">
                <div style="text-align: justify; margin-right: 14.15pt;"><img width="112" height="63" src="image03.jpg"></div>
              </td>
              <td style="width: 75%; vertical-align: top;">
                <div><img width="85" height="85" src="image02.jpg"></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="text-align: justify; margin-right: 14.15pt; font-weight: bold;"> <br>
      </div>
      <div style="text-align: justify; margin-right: 14.15pt; font-weight: bold;">Disclaimer</div>
      <div><br>
      </div>
      <div style="text-align: justify; margin-right: 14.15pt; font-style: italic;">This press release contains certain<a name="z_cp_text_1_127"></a> &#8220;forward-looking&#8221; statements within the meaning of applicable securities laws, including the Private
        Securities Litigation Reform Act of 1995.&#160; Forward-looking statements may be identified by words such as &#8220;at this time,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;on track,&#8221; &#8220;plan,&#8221; &#8220;scheduled,&#8221; and &#8220;will,&#8221; or the negative of these and similar
        expressions. These forward-looking statements, which are based on our management&#8217;s current expectations and assumptions and on information currently available to management, include statements about the timing and progress of clinical trials
        (including with respect to patient enrollment and follow-up), the timing of our presentation of data, our relationship with, and the performance of, our collaboration partners, and the sufficiency of cash to fund operations. Such forward-looking
        statements are <a name="z_cp_text_1_128"></a>made in light of information currently available to us and based on assumptions that Nanobiotix considers to be reasonable.&#160; However, <a name="z_cp_text_1_130"></a>these forward-looking statements are
        subject to numerous risks <a name="z_cp_text_1_133"></a>and uncertainties, including with respect to the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to the evolving situation.
        Furthermore, many other important factors, including those described in our prospectus filed with the U.S. Securities and Exchange Commission on December 11, 2020 under the caption &#8220;Risk Factors&#8221; and those set forth in the <a name="z_cp_text_1_135"></a>universal registration document of Nanobiotix registered with the French Financial Markets Authority (Autorit&#233; des March&#233;s Financiers) under number R.<a name="z_cp_text_1_137"></a>20<a name="z_cp_text_1_139"></a>-010 on<a name="z_cp_text_1_141"></a> May 12,<a name="z_cp_text_1_143"></a> 2020 (a copy of which is available on www.nanobiotix.com)<a name="z_cp_text_1_145"></a>, as well as other known and unknown risks and uncertainties may adversely affect such
        forward-looking statements <a name="z_cp_text_1_147"></a>and cause <a name="z_cp_text_1_148"></a>our actual results, performance or achievements to be materially different from <a name="z_cp_text_1_152"></a>those expressed or implied by the
        forward-looking statements. <a name="z_cp_text_1_153"></a>Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those
        anticipated in the forward-looking statements, even if new information becomes available in the future.</div>
      <div><br>
      </div>
      <br>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); text-align: center; margin-left: auto; margin-right: auto; border: medium none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image01.jpg
<TEXT>
begin 644 image01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  \ 04# 2(  A$! Q$!_\0
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M=#TFULK"YM=+L8;D0(1+';HKC*X/(&><G\Z^8OB%_P G86O_ &%M,_\ 08*
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M$7J3ZDGN2<DGU->;?&3X0S?$/7K'48M7CL1;6_D%&@+[OF+9SD>M 'J&C?\
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MI:5MS,TCL[$GW9C0!=HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#F]*_Y)Q9_]@E/_ $2*:/M/]O:7]D,(;^S'SY@)
M'WXO2M:ST/2;+/V/2[&WRGEGRK=$RO\ =X'3VJX((ED601('5=BL%&0O' /I
MP./:@#%N/M?_  E$7V<P!_L)W;P<9WCIBMU-VQ=^-V.<=,U4OM*T_4)$>_L+
M2Y= 55IH5<J#U )%6H8TAB2*%%CC10JHHP% Z #L* '4444 %%%% !1110 4
F444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image02.jpg
<TEXT>
begin 644 image02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0L!VH# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4 7**Q9?$=G#]YQ^=49?&^FQ=95_.@#J**XQ_B)I*=9E_.H6^).D ?ZY?SH
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M:Z)J+64P8-C!KUSPSXU?*1F7]: /H(,#T-+7/Z%J8NX%8MG(K?# T +1110
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M!=I*H(859!R*\:\+^,_/*!Y?UKT^RU:&>)<."2* ->BJZ2;^14PS0 ZBBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M ^S(949!A@:FKP_P9X\N+TH)I.OJ:]?L=2AGA4[P210!HT4BL&&12T %%%%
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M&FWK6L@(.*])\,^*Y!*B%^/K0!]-V]P)ER*L5R'AG5X[BW4LXSBNK29''!H
MDHHHH **** "BDW"C- "/]PUY5\1O]1)]*]5?[AKRKXC?ZB3Z4 ?-.L?\?C_
M %K-K3U?_C]?ZU0P,4 1U(K 4TTV@![,#2 X--IR@4 /+C%;'AWF_C^M8Y Q
M6QX=_P"/^/ZT ?3_ (! ^R)]*]"'05Y[X!(^R)]*]"!XH 6BBB@!CR!!FN=\
M0:@JVD@SVJ]K%W]F@+9QBO(_$_BM5WQ^9^M 'G_CC49#<OM<]?6O/)+AG)R<
MUN>(=0%W,QW9R:YX &@!I.:;4C 5'0 N30#24HH >'HSDTJJ#4T5L[N,"@"[
MIVFM<L,"O4?!WALB5"\>>?2JO@30%N7C\Q:]YTCPU;6\2LJC./2@"71=)@BM
MD_=+G'I6]'$L8P!BB*(1*%':I* "BBB@ HHHH **** "BBB@ HHHH *:T:L,
M$9IU% &=>:9;31-NB4GZ5X]XX\++-O,40'T%>XL-PQ63?Z-#=(VX"@#X^U/P
M])9NQ(/%8$F$8@U]!>//#T4,<A1?TKP?4K1X[AOEXS0!2WBC>*C((ZT"@!2<
MTVI% I& H 0&GB0KT--4"G$#% &]X=O9([Q,N<9]:^C?!>M*MJ@8]A7S#IDG
MEW"FO6O"^L; B[J /HBVO%G Q5NN2\.7GGQKSFNL7I0 M%%% !1110 4444
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M **** "FORIIU(W2@#S[QC9>?&XQ7A/B#1_+=VVU]*:W;K*K9KR/Q;IZ+&Y
MH \*O(_+E(JK6IJ\>VY8>]9?2@!X4T%2*0.106S0 VER:2B@"Q;,0X-=AH5T
MRS(-W>N*1L&MO2;HK<)SWH ^EO!5UF),FO1HI RBO'O UV3%'S7JMG+N4<T
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M/P5,0B5[%HTA95H Z9>E+34^[3J "BBB@ HHHH **** "BBB@ HHHH ****
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MBZD1M:O)/')'E2?2O6-4^ZU>1>-_]7)]* /"M4_X^G^M4*T-2&;I_K538,4
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MI6FT 2,14=%.49H ;6YX=_X_H_K604&*U_#P_P!/C^M 'T[X"(^R)]*]#4C
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M\<1&@#SWQ&&\J2O!?%V?/?/K7O?B-SY4E>"^+CF=_K0!Q>#GB@@TN[!I"V:
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M* &[N:>!FK.GV?VF=4]:]'T/X=C4(U;'6@#S#R6/04"V<]J]]M?@ZC@&K?\
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M2?2O6]4^ZU>1>-_]5)]* /"M3YNG^M4MAQ5[4CBZ?ZU3W\4 ,QBC<103FDH
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MS]:]?T'4OM<:G=G(KY'T+476Z0;CUKZ)\#:D#;IENU 'J Z4M5H+@2*,&K-
M!5*^_P!4:NU2OCB(T >>^(]WE25X+XNSY[_6O>_$;_NI*\%\7',[_6@#B^<T
M'-+NP:0MF@!E%%% !3H_O4VG1_>H ZG1<;ES7LO@O;N3%>-:,N66O9/!289*
M /9K+_4+]*M55LO]0OTJU0 4444 %%%% !1110 4444 !Z5FWVG1W2D.N:TJ
M* /*/%GA6 P.R1C./2O"/$&@30W#E4./I7U[J&G"[C*D=:\Z\3>"E:%Y HH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M(W2EI#TH P]34E6KR?QG;221O@5[1<VGF@US>J^%S>*1CK0!\G:EIER;EB$/
M6J?]F7/]PU](S_#,R2%MGZ5%_P *O/\ <_2@#YQ_LNY/\!I?[(NC_ :^C?\
MA5Y_N?I4B_#+'\ _*@#YN.D7(_@-)_9-S_<-?2+?#'/\ _*FCX8$'[@_*@#Y
MZMM)N=WW#77^'M.G6X3*GK7KD?PUVG[@_*M*R\!_9W#;>GM3&F:?@^)DMTR.
MU=J.E9>F:=]C0+CI6K2$%%%% !1110 4444 %%%% !1110 44F::7Q0 ^D*@
MTT/FE+8H Q=:T\7-NRA<YKQOQ/X*>5W<1?I7O9(;@BJMU817$1!0<CTH&F?'
M6L^&Y[61@(R/PK#_ +*N<_<-?5&L> UO7)5!S[5B?\*O.?N?I3$?.7]E7/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M 4444 %%%% !28'I2T4 )M'I3&B4]0*4OB@'- %:2PBDZ@54DT&VDZJ/RK6
MI: .?;PK9L<[!^5)_P (I9_W!^5=#10!@#PO:#^$?E4J>';5.BC\JVJ* ,U-
M'@3HHJPEE&G0"K5% #515'04N!Z4M% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 (:;DTXG%,WC-,8\4M(
M#FEI""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ INP4ZB@! ,4M%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 ,)-(":?BC IW !2T44@"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M&E :4+BEHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7_GI^M'_  GJ?W_UH^K,/:GM?VV'^^*/ML/]\5XI_P )XO\ ?_6C_A/%_O\
MZT?56'M3VO[;#_?%'VV'^^*\4_X3U?[_ .M'_">+_P ]/UH^K,/:GM?VV#^^
M*/ML/]\5XI_PGJ?\]/UI?^$\7_GI^M'U9A[4]J^VP_WQ1]MA_OBO%/\ A/4'
M_+3]:/\ A/%_YZ?K1]68>U/:_ML/]\4?;8/[XKQ7_A/%_P">GZTG_">+_P ]
M/UH^K,/:GM?VV'^^*/ML/]\5XK_PGB_\]/UI/^$]3_GI^M'U9A[4]K^VP_WQ
M1]MA_OBO%/\ A/%_YZ?K2_\ ">+_ ,]/UH^K,/:GM7VV'^^*/ML/]\5XK_PG
MB_\ /3]:/^$\0?\ +3]:/JS'[4]J^V0_WQ1]MA_OBO%/^%@)_P ]/UI?^$\0
M_P#+3]:?U5A[0]J^VP_WQ1]MA_OBO%/^$]4?\M/UH_X3Q?\ GI^M+ZLQ>U/:
M_ML/]\4?;(?[XKQ7_A/4'_+3]:3_ (6 A_Y:?K1]58_:'M?VV'^^*/ML/]\5
MXK_PGBG_ ):?K2?\)ZG_ #T_6CZLQ>U/:_ML/]\4?;8?[XKQ3_A/%_YZ?K1_
MPGB_W_UH^JL/:GM?VV'^^*/ML/\ ?%>*?\)ZO]_]:/\ A/%_YZ?K1]68>U/:
M_ML']\4?;8?[XKQ3_A/4_O\ ZT?\)XO_ #T_6CZLP]J>U_;8?[XH^VP_WQ7B
MG_">K_?_ %H_X3U?[_ZT?5F'M3VO[;#_ 'Q1]MA_OBO%/^$\7^_^M'_">I_S
MT_6CZLP]J>U_;8?[XH^V0_WQ7BG_  GJ_P#/3]:7_A/D_P">GZT?56"JH]J^
MVP_WQ1]MA_OBO%?^$]4_\M/UI/\ A/%_YZ?K1]58>U/:_ML/]\4?;8?[XKQ/
M_A/5_P">GZTO_">I_P ]/UH^JL/:H]K^V0_WQ1]MA_OBO%O^$^3_ )Z?K2?\
M)XO_ #T_6CZJQ^U1[5]MA_OBC[;#_?%>*?\ ">+_ ,]/UH_X3Q#_ ,M/UH^K
M,7M3VO[;#_?%'VR'^^*\5_X3U!_RT_6D_P"%@)_ST_6CZJQ^T/:_ML/]\4?;
M8?[XKQ7_ (3Q#_RT_6D_X3U?^>GZT?56+VI[7]MA_OBC[;#_ 'Q7BG_">*?^
M6GZT?\)\@_Y:?K1]58*J>U_;(?[XH^VP_P!\5XI_PL!#_P M/UI?^$\7_GI^
MM'U5C=0]J^VP_P!\4?;8?[XKQ3_A/4_YZ?K2_P#">+_ST_6CZJQ>U/:OML/]
M\4?;8?[XKQ7_ (3U!_RT_6D_X3U#_P M/UI_56'M3VO[;#_?%'VV#^^*\5_X
M3Q?^>GZTG_">+_ST_6E]68>U/:_ML/\ ?%'VV'^^*\5_X3Q?^>GZTG_">I_S
MT_6A85A[4]K^VP_WQ1]MA_OBO%/^$]4_\M/UI?\ A/%_YZ?K1]58>U/:OML/
M]\4?;8?[XKQ3_A/%_P">GZTO_"=K_P ]/UH^K,/:GM7VR'^^*/ML/]\5XM_P
MGR?\]/UI/^$\4_\ +3]:/JK'[5'M7VV'^^*/ML/]\5XI_P )XH_Y:?K1_P )
MZO\ ST_6G]58O:GM?VV'^^*/MD/]\5XI_P )ZG_/3]:=_P )\G_/3]:7U5C5
M5'M/VV'^^*/ML/\ ?%>*_P#">*?^6GZTG_">K_ST_6CZJQ>U/:_ML/\ ?%'V
MV'^^*\4_X3U?^>GZTO\ PGJ?\]/UH^JL/:H]J^V0_P!\4?;8?[XKQ;_A/D_Y
MZ?K2?\)XO_/3]:/JK'[4]J^VP_WQ1]MA_OBO%/\ A/5_YZ?K1_PGJ_\ /3]:
M?U5B]J>U_;8?[XH^V0_WQ7BH\?(/^6GZTO\ PGR'^/\ 6E]58_:H]I^VP_WQ
M1]MA_OBO%?\ A/%_YZ?K2?\ ">K_ ,]/UH^JL7M3VO[;#_?%'VR'^^*\5_X3
MQ?\ GI^M+_PGJ#_EI^M'U5C]J>T_;(?[XH^VP_WQ7BO_  GJ'_EI^M'_  GB
MC_EI^M'U5A[4]J^V0_WQ1]MA_OBO%O\ A/D_YZ?K2?\ ">+_ ,]/UH^JL/:G
MM7VR'^^*/ML/]\5XM_PGR#_EI^M)_P )ZI_Y:?K1]58>U1[5]MA_OBC[9#_?
M%>*_\)ZH_P"6GZT?\)\G_/3]:/JK#VJ/:OML/]\4?;(?[XKQ3_A/4_YZ?K3O
M^$^3_GI^M'U5B55'M/VV'^^*/ML/]\5XK_PGBG_EI^M)_P )ZO\ ST_6CZJP
M]J>U_;8?[XH^VP_WQ7BG_">K_P ]/UH_X3U/^>GZT?56'M4>U_;(?[XH^VP_
MWQ7BW_"?)_ST_6D_X3Q?^>GZT?56/VI[5]MA_OBC[;#_ 'Q7BG_">K_ST_6C
M_A/%/_+3]:?U5B]J>U_;(?[XI?MD/]\5XLOCU!UD_6E/C^,])/UI?5F'M3V?
M[;#_ 'Q1]LA_OBO%?^$\7_GI^M+_ ,)\G_/3]:/JK'[4]I^VP_WQ1]LA_OBO
M%?\ A/%_YZ?K3AX^0=9/UH^JL7M3VC[9#_?%'VV'^^*\8/CY#TD_6F?\)XO_
M #T_6CZLP]J>U?;(?[XH^VP_WQ7BW_"?)_ST_6D_X3Q?^>GZT?56/VI[5]MA
M_OBC[;#_ 'Q7BG_">K_ST_6C_A/%_O\ ZT?5F+VI[7]MA_OBC[;!_?%>*?\
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M",D=33]XIP84<B!R(2A'<TGED]S4Q84!A3]FK!S$7DD=S1M;U-3%A3=ZTN5
MI#/+/J:0J1W-39%'%'(A<Q"$)[FE,9'<U+Q02!1R(=R$ ^II=OO3BP/2FX.:
M'!!S"8/J:41D]ZD&.].[4<B#FN0%".YH /<U,2!49.>E'(@YA"OO3,-GJ:>
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M!,HF37J>FJ JUY;X3/RIBO4-,)VK7+5AH:0>IO+TI::O2G5Q&X4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %-?[M.IK_ '30!R6O'AJ\L\0-PU>I:^I*M7EGB!2-U>C0EH<U1ZG
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MY4TZ;=#_ )8M^5?1O_"+6'_/%?RIW_"*Z?WA7\J/K0N1GSBNFW1_Y8M^5/\
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M:, A;#BO0O"<?F,M<%%"7<8%>B>$1Y)7=7-5O;0-#TNS18(U)..*CU/Q&EA
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*;UK%ICN=';>+6MDV43>*FF%<WY:FC8!5(&RU>WQN2:I1C!S4FT4N!6J:))
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\L\R0<;3^5 DDS]TUZK_ ,(G;'_EF/RI5\)VV?\ 5BM^>QBXGEPEDQ]P_E3
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M1*]/TW[JUYEX1^XF:]0T[&U:X:[T-X,V5Z4ZD7I2UYQN%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !37^[3J:_W: .2UX\-7EOB#G=7J6O$8:O*_$)X;%>CA]C"=S@[C_7'ZTU6I
M)R?./UIZ!<5Z$#%I#AS1G%+Q2$CO5V(8G6C%&1VI*6MR6+1116EB1<T4W<*4
M<]*5AW$)Q49.:E(]::0O:LIW-(V-'2%/G@UZOX?;")7E>D?Z\5ZKX?QL2N.K
M<UBT>A:8?D%:G:LO3,;!]*U.U>;/<Z8[%>?H:X;Q4<1-]*[B?H:X?Q5CRF^E
M;42)'C&K/_I#?6LHGFM;5MOVAOK62W6O3ILYI #29HR*7&>E;ZF3N*K8IQ?(
MIH7UH.!5)D"&C-)D9IP%*Y23%I":"0*3(I7+LPZTN*;D4H:G<EA13N,4VJN0
M.#XH+9H!7O3'Y^[6;12(Y#BM31'S./K6.^<_-6SH13SQ]:RGH;1/6- 7*I7H
MFFC]V*\]T#[J8KT/3O\ 5BO-KLZ*;-'M4,I^4U-4<@!4URHTD>=>,C^[>O%]
M1.)V^M>U>,U_=O7BVHC_ $AL^M>CA]C%F=OYJ0<BF?+FG@CM7?%(P;0A;%(&
MS3MH-)M K:RL0Q-^VCS=W&*7"GK2X0=*FY @AW<T[R=HI-Y'2D\W/!I;CNQC
M3>7VIR71)XXJ00K)UI&C2.I<"D7;;4G@(.XUT&G^+WMV&7/'O7&EE/2FX/6L
MY44S2+/8=.^(R@!2:ZFQ\:Q7&/F'-?/"S-&<@U;AUJZ@QL8UC+"Q-E,^H+/5
MXKD#YQ^=: E1APPKYGM/&=_ 0-Y_.NQT7QW(VWSI?UKCGAFGH:*29[5P>]&
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MKQ?QRF6>O9[S_4-]*\3\=NX=\5K1W%+8\TEC_>&D5"*;O8R'-3 BO5IO0YI
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@J[D\J$#@TI(Q4QTN[;_ %<9/X5:L_#^HRL-T#8^E9RD4HF:#D\"KEK:O,X
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FO\
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M$JNPK+C\721]#5@>.YT'#5R5(2Z%Q9ZOI%A%:0A6 R*UQ+&O0BO$O^%@W/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8GS_ /V!=>A_*G#0+GNI_*O?O^$-A]!2?\(;#Z"FL78?LCP(^'[C^Z?RIO\
MPC]S_=->_P#_  AL/H*/^$-A]!3^N"=$\ _L&Z]#2_V#=>AKWW_A#(?04O\
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MX7TV:%5R#7I&G1,JC-%IH:6P& *U(X!'6,ZKD5&-B9>E+116!84444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI:\8@^+B.>HK;T_XD173@%AS0!Z916)8:[!=(#YB\^]:B7,;]'!_&@">BD#
M]#2T %%%% !29%!JO<2>6A:@"QFEKSW7_'8T@L#VKEA\9$W8IV ]KHS7C/\
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M1>W/V6%G]* +=&:\SUKXBG392NT\&L/_ (6^,\C% KGM&:*\9'Q>3U%#?%]
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M?"DT )V'CVK#N;&2!L%3^5 %^'Q'>0_=<_G6G;^.]4MR-LC?G7*C*]12_>H
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MJ-E\*IIU#8-:L?PDE Z&@#QGS)$]:7[7(.]>OS_"27!(!KG]1^'$UF#\IXH
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M5)AM;%% %O\ M"8]S3OMTWJ:I"IX1O8+ZTF@)OM\P[FF_P!H2^IK;L?#<EZ
M0#S6JG@.9A]TTK@<=]OE_O&E_M"7U-=G_P *_F_NFD;P#,/X30!QGV^7U-6;
M&\D-PO/>NF/@6;^Z:LV7@>99E.T]: .W\&3,R)DUZ_I!^5:\\\+>'GME7(/%
M>EZ;:F-5H W$^[3J:H^6G4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C?=-<)XR_U+_2N
M[;[IK@_&7^I?Z4 >!^(?]:_UKA;O_6&NZ\0_ZU_K7"7G^L- $("XH4#>*BI\
M7WQ0!Z#X3LXYF3<*]CT/0K5U7*BO)/!WWDYKV_P_@*G- '06_AFT,8^0?E4O
M_"+V?]P?E6M:LOECD5/O7U% &%_PBUG_ '!^5-/A2R/\ _*M_>OJ*-Z^HH P
M5\*V:]$'Y4__ (1FT_N#\JV]Z^HHWKZB@#"_X1>S_N#\J<OAFT!^Z/RK;WKZ
MBER/6@#+CT.WCZ**NPVB0_=%6** $/"UQOBW)@;'I79'H:X[Q6VV!L^E '@7
MB17\U^.]>>WV1(:](\23KYCC%><Z@V930!1#&E!.X4W-*OWA0.R.UT*!K>[:
M!RA>-RC&.174D''#*2&'N"0>U>Q^%QRE>/Z2;3^TIO[/\_[%YK?9_M&/,\O/
MR[\<;L8SCC->P>%VY2BP]#U?3O\ 4+]*O51T[_4+]*O4$A1110 AZ5R7BMB+
M=L>E=:>E<EXK.+=OI0!X'XFD?SI*\ZU DR'->B>)G'G25YWJ!_>&@#/Q2CK2
MYH!^:F,Z;0<[UQ7K_A/=O2O(_#^-ZU['X5(W)0!Z_I/_ ![+]*76/^/-_I1I
M7_'NM&L?\>;_ $I"/FGXC?\ 'Q)]:\NV@L:]1^(W_'Q)]:\L+8<T#'E%IAP.
ME+NW4W;0)FYX>B$MZBMTS7T3X.\/6D]HA91TKYY\,_\ '\GUKZ<\$?\ 'FG/
M:@#?7PM9 <(/RIW_  B]G_<'Y5MH1@<T_</6@#!_X1>S_N#\J:_A2R<<H/RK
MH-R^HI-Z^HH XZ_\#V,D9Q&/RK@->^'T #LL7Z5[7-/&BDEA7+ZWJ]LD#@[<
MXH ^7_$FB+8.P"XQ7(D[6(KTSQW>1SRR;,5YJRY<T  ;/6I P7D5$4Q3>: .
MC\/W;B]0 ]Z^D/!%TQM4R>U?,WAX$WJ?6OI3P-"3:I]*!H](AD+ 5.3A:K0K
ML6J5_JJVJG)H$<[XOUJ;3X7,;8P*\%\1>.KV:62,R'&<=:]$\=:\D\+@'M7@
M&K2F2[<Y[T 1WMZ]W*68\FJF#2 T\,* $&<UH6FFW%TP\M"<U3C^:0<5ZSX!
MTQ+AH]R _A0!!X0\(3RRH9HCC/I7N.B^#K.*!&*#./2M#2=$A@B4B,#CTKH8
MHPB@ 4 4X=)@A7"J*G^QQCL*LT4 5&L8V'050N_#MK= [U'/M6U10!Y1XH\#
MP&)C#%DX]*\7UWPA=6\KL(2 #Z5]<36Z2CYE!KBO%VEP"S=A$N<>E 'R1=VK
M6\A5ABJW-=3XLM_+O7VKCFN8SCJ* $!(.:VM+\07&GLOEL1BL1FS30>: /<?
M!WCB\N)4220XSZU[GH^I+<6REFY(KY'\+WOV>=3GO7N?AGQ"&2--WZTP/6RP
M=>*RM2A!A;Z5-IUQYT(--U$_N&^E 'S[\1(PK25XW-_K37L_Q&/S2?C7C$W^
MM-(!JFI<\5"#BEW4QDB(9' %;5IH5S.FY8R:S]+4/=(#ZU[EX1TJ*:T7,8/'
MI0(\5O=*FML[T(K+/RFO;/%WAP,&*)CZ"O*[_1WMG8D&@#+BN7B.5-=5X<UZ
M6.Z0,V!]:Y%EVMBIK:4Q."#BC0#ZH\)^)K<VZ!Y1G'K7?VE]%<@%&S7R1H6O
MR13(OF'KZU[MX-UOS8DW/G\:+@>GTA/%5H+I95&#4S'BD!POCL_Z$_T-?+WB
M;_C_ )/K7TYXZ;_0W^AKYB\2G_3W^M S I1UHS2@\T!9&A9_>%>M^ ?];']:
M\DL_O"O6? ;8EC^M CZ"TO\ X]4^E)JO_'NU-TJ3_1D^E.U0_P"C-0!X_P"*
MBVYZ\=\09WMFO9/%+C<]>.>(6R[4 <JW6DI6ZTE &GID8>0 UZ1X=TR*1TR*
M\ZTDXE%>I>&)!O3F@I6/6/#WAVU>!<J.GI70_P#"+V?]P?E5;PVZ^0O(Z5TN
M]<=102S"_P"$6L_[@_*C_A%K/^X/RK=WKZBC>OJ* ,+_ (1:S_N#\J#X6LS_
M  #\JWMZ^HI-Z^HH P/^$3LO[@_*G+X6LU_@'Y5N[U]12[E]11<#$'AJT'\(
M_*K,&C00'*J*TLCUI: &H@08%.HHH 0C-5;BS25#D5;HH \L\7>&#=*^R//X
M5XMKWA2:T9V,1'X5];R6\<@.Y0:XCQ9X<CO86"1CD=A3N.Y\C72&*0J1C%0#
MFO2_$7@.:&5Y IQFN O;![.4J0>*+A<@3Y3D5K6&OW-DZA&(Q6,'P*:7YI"/
M=/!7C)F*">3\S7J$OB^S6V!$PSCUKY.L-4>U(VL1^-:4GB>=DV^:WYT] /9_
M$?C&*2)U64'\:\7U_5GN+AB&SDUFSZM-*3F0G\:SY)2YR318!'D9SS3 #FG+
MR<5H6>FO<,, T#$LM.EN6&U2<UZ+X2\*223(9(CC/I5SP;X9,C)N3]*]MT;P
MXEO&IV <>E(1'H/A2UA@1B@SCTKJ[>T2W7:HIT$0B0 "IJ &-$&'-4)](@G^
M\HK2HH PO^$9M,_='Y4'PS:?W!^5;M% &!_PB]G_ '!^5._X1FT_NC\JW:*
M.;N_#-H(6.T=/2O#OB%ID5L9-@]:^C;S_4-]*\!^)?63\:=P/"YQB4U'BI9S
M^^:H\TTQB<U>TM ]T@/K5+-7M*/^EI]:3 ]]\":);7$*%U'2O38?"]EM'R#\
MJ\^^'TF(8_I7K-L^Y119",W_ (1>S_N#\J0^%;,_P#\JWQTI:0'._P#")67]
MP?E3E\*V:G(0?E7044 9T&D00#Y0*N)"J=*EHH **** "BBB@ HHHH ****
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M+@#Y\Y]Z^5=$O+AKA<NW7UKV3PQ-*RIEC0![7:7'G*#FKE8.B$F)<GM6\.E
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M% '@7BO1+5I78@9KRS5K2."0A*]S\3Z-(V]LUXSXAM6@E8'UH YK!S2XIP8
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MV/:!/RH ^9='\(W4<RDPM^5>J>']&FA5<QD?A7HJ:#:(V1"OY5>BL88QP@%
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M'2N^K,U.R^TQE<9H ^4_$NALMRY"=_2N*NK<PL1BOI7Q-X3)B>39^E>%>)[
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MZ4 ?,4MLT;'*XJ C%=[XGT,V1;Y<?A7!R@AR* &4E%** #!H YJ0,,4TD9H
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M\Z:;Z4_Q'\ZZ_P#X5OJ/]P_E1_PK?4/[A_*@#C3=2'^(_G0MU(I^\?SKLO\
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MC;P?=W\SE%/)]*\[D^'6H!C\A_*@#A:4'%=POPYU!OX#^5/_ .%::C_</Y4
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M/]T?E6W10!B?V!#_ '1^5']@0_W1^5;=% &)_8$/]T?E33X?A/\ "/RK=HH
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M.J#\JV<4N* ,$>'8 ?NC\J<?#\./NC\JW** , >'80<[1^568M&BCZ**UJ*
M*\-LL7058HHH **** "BBB@!I12.0*I7&G13=5%7Z8P- &#+X;@D/W1^549_
M!EO,"-H_*NJ .:D% 'GDOPUM9&SM'Y5&/AC:^@_*O2** /.A\-+4=A^57+?P
M#;0]%'Y5W-% ',1>$X(_X1^578="AA/"C\JVJ* *D4"1# 4587;Z"G%1494T
M 2<4M,4&GT %(1FEHH 9LHV<8I]% &=<Z9'/U JI_P (_#G[H_*MRB@#$_L"
M#^Z/RI/[ @_NK^5;39IF&S0!DKH$*G.T?E5^"Q2$< 5;%+0 T+BG444 %%%%
M !1110 A%0R6ZR=0*GHH S9-)B?JH_*JQT&$G[H_*MNB@#$_L"'^Z/RIA\.P
M'^$?E6YO%*#F@#%30(5_A'Y5<@TZ.'HHJ_10 BKM&*1EW#%.HH I2V"2=0*J
M2:)$_51^5;%% &"?#L!_A'Y4G_".0?W1^5;]% &"/#L _A'Y4\:!#_='Y5MT
M4 8G]@0_W1^5,/AV _PC\JWJ* ,(>'H!_"/RIW]@P_W1^5;=-8&@#%.@0'^$
M?E3?^$=@_NC\JV0&S4@H Q!X?A'\(_*E_L&'^Z/RK;HH PSX?A_NC\JG@T>*
M$Y"BM6B@"#[.NW&*K2::LG6M"B@#%?0HF/*BF_\ "/P_W1^5;E% &)_8$/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *0C-+10!&4IP7%.HH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
IBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image03.jpg
<TEXT>
begin 644 image03.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "7 0D# 2(  A$! Q$!_\0
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M9P,XSUQ7T!\6/ J^*M :^LHD_M:P0O&1&6>>, DQ#').>5X//'&XFOG'1?\
MD.Z?_P!?,?\ Z$*!GVC6'XS_ .1%\0_]@RY_]%-6Y6'XS_Y$7Q#_ -@RY_\
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MJ4DCD4,KJ1@@@\$$=J^2?'OA-O!GBJ?2P[RVS*)K663&YXVSUQW!#+VSMS@
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M32=;O]1LM/N_.N--E\J[3RW7RWRPQE@ >4;IGI7-?\*@\%_V/_9_]F-NV_\
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M!>^CC,]BR6TR/'<("8V5M@VG=@9R.">QJYXNOYM>\#>#DNP@BU[4-/2^AC&
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ME22>8C,7#?*I Y8C&?X<]Z]FAABMH(X((DBAB4)''&H544#   X  [5SU]X
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
B4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
